A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty

University Hospital Freiburg

Overview

The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty. The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Conditions

Corneal Transplantation

Interventions

Mycophenolate Mofetil 2x 1gDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Keratoplasty with increased risk for immunologic graft rejection in the abscence of other risk factors for graft failure. (repeat keratoplasty, steroid-response, limbo-keratoplasty, oversized graft. Exclusion Criteria: * Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.

Locations (1)

University Eye hospital

Freiburg im Breisgau, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.